Testosterone Injectable Shortage
May 12, 2021 update: Shortages begin
Health Canada is aware of a possible Testosterone injectable shortage pending and is actively monitoring the situation and working closely with all stakeholders across the drug supply chain to identify mitigation strategies. Two Market Authorization Holders, Bausch Health and Pfizer Canada are currently reporting anticipated shortages on the drugshortagescanada.ca website. For further information on availability, please contact the manufacturer(s) directly.
- Pfizer Canada is anticipating a shortage for Depo-Testosterone starting June 18, 2021 until April 2022: Drug Shortage Report for DEPO-TESTOSTERONE INJ 100MG/ML (drugshortagescanada.ca).
- Bausch Health is anticipating a shortage for Delatestryl starting May 14, 2021 until July 15, 2021: Drug Shortage Report for DELATESTRYL (drugshortagescanada.ca).
A third Market Authorization Holder has recently entered the market — Taro Pharmaceuticals — which currently sells testosterone cypionate in Canada (product monograph). Taro is not reporting a shortage and has confirmed that it has adequate supplies available.
Health Canada will continue to monitor Testosterone injectable supply and will keep CSEM informed if any delays are reported for the expected resupplies.
March 31, 2021: Testosterone supply issues
CSEM has been meeting with Health Canada's Drug Shortage Unit regarding supply issues for testosterone injections: testosterone cypionate (Depo-Testosterone) and testosterone enanthate (Delatestryl). We have learned that supply issues are due to Pfizer prioritizing COVID-19 vaccine production until mid-2022. Bausch Health and Taro Pharmaceuticals have increased their supply to help mitigate any shortages. Note that Taro-testosterone is not currently covered under the Ontario Drug Benefits program. Taro-testosterone is not interchangeable with Depo-Testosterone. If switching products, physicians will need to write new prescriptions as it is not an automatic switch at the pharmacy.